Preface.

Area of Science:

• Infectious Diseases
• Pharmacology
• Urology

Background:

• Lower urinary tract infections (UTIs) are a common condition, accounting for a significant percentage of general practitioner consultations and antibiotic prescriptions.
• Uropathogenic bacteria are developing resistance to widely used antibiotics like trimethoprim and ampicillin, with resistance rates often exceeding 30-50%.
• The emergence of antibiotic resistance necessitates a reevaluation of current UTI treatment strategies and the exploration of alternative antimicrobial agents.

Purpose of the Study:

• To review current perspectives on the diagnosis and treatment of UTIs in light of evolving microbial resistance patterns.
• To evaluate the potential role of pivmecillinam in the management of UTIs, considering its pharmacological properties and clinical efficacy.

Main Methods:

• This supplement synthesizes information presented at a March 2000 meeting in Vienna, Austria, sponsored by Leo Pharmaceutical Laboratories.
• It draws upon existing clinical experience and scientific data regarding UTI treatment and antimicrobial resistance.

Main Results:

• Antibiotic resistance to common UTI treatments is a growing concern, complicating clinical decision-making.
• Pivmecillinam, hydrolyzed to mecillinam, exhibits a novel mechanism of action, rapid bacterial penetration, and reduced susceptibility to beta-lactamases.
• Clinical experience across multiple countries suggests pivmecillinam is a suitable candidate for UTI treatment due to its spectrum of activity and safety profile.

Conclusions:

• The increasing prevalence of antibiotic resistance in uropathogens requires a reconsideration of treatment options for UTIs.
• Pivmecillinam's unique properties and established efficacy suggest it could play a significant role in the contemporary management of UTIs.